Our Take
The numbers come from a vendor whitepaper with no independent reproducer, so treat them as an upper bound, not a floor.
Why it matters
Drug development timelines and costs are the bottleneck in biotech. If simulation can credibly compress either, it changes which programs get funded and which get shelved.
Do this week
R&D leaders: Request the methodology and independent validation data from vendors before budgeting for in silico adoption this quarter.
ZS releases in silico trial economics
Consulting firm ZS published a whitepaper claiming AI-driven simulation could reduce clinical trial costs by up to 60%, shorten timelines by approximately 40%, and improve success rates 2.5-fold (per the company's resource page). The analysis frames in silico clinical development as a lever for pharma economics.
The claims rest on modeled outcomes rather than independent trial data. ZS does not disclose the methodology, trial cohorts, or baseline comparisons in the available excerpt.
The catch: vendor models without external validation
In silico trials are real and growing. Simulation tools do compress preclinical cycles. But a 2.5x success-rate lift and 60% cost reduction are extraordinary claims. They sit on the border between realistic upside and worst-case marketing.
The problem is not the numbers themselves—it is that no third party has audited them. A consulting firm has inherent incentive to project outsized ROI; that does not make the numbers false, only unconfirmed. Pharma teams will see "60% cost cut" and ask their internal teams to deliver it. Reality will diverge.
Independent academic or industry benchmarks, or at minimum a published case study from a named biopharma partner, would anchor these claims. Absent that, they remain a vendor position, not an empirical fact.
How to read this responsibly
If you are evaluating in silico platforms, the ZS figures are useful as a ceiling, not a floor. Start by asking vendors:
- Which therapeutic area and trial phase does this 60% apply to?
- What was the baseline cost assumption?
- Who independently validated these numbers?
- Do you have a named customer willing to disclose actuals?
Simulation reduces iteration cycles and front-loads design work. Both are real. But the jump from "faster preclinical" to "2.5x trial success" requires evidence that this whitepaper does not provide.
Build your own model using publicly available trial data (FDA, EMA, ClinicalTrials.gov) and your own portfolio assumptions. Use the ZS figures as one input, not the input.